Rhone Ma Holdings Bhd banner
R

Rhone Ma Holdings Bhd
KLSE:RHONEMA

Watchlist Manager
Rhone Ma Holdings Bhd
KLSE:RHONEMA
Watchlist
Price: 0.695 MYR 2.21% Market Closed
Market Cap: 155.9m MYR

P/B

0.9
Current
2%
Cheaper
vs 3-y average of 0.9

Price to Book (P/B) ratio compares a company`s market value to its book value. It shows how much investors are paying for each dollar of net assets on the balance sheet.

P/B
0.9
=
Market Cap
MYR156.3m
/
Total Equity
175.7m

Price to Book (P/B) ratio compares a company`s market value to its book value. It shows how much investors are paying for each dollar of net assets on the balance sheet.

P/B
0.9
=
Market Cap
MYR156.3m
/
Total Equity
175.7m

Valuation Scenarios

Rhone Ma Holdings Bhd is trading below its 3-year average

If P/B returns to its 3-Year Average (0.9), the stock would be worth MYR0.71 (2% upside from current price).

Statistics
Positive Scenarios
4/4
Maximum Downside
No Downside Scenarios
Maximum Upside
+154%
Average Upside
54%
Scenario P/B Value Implied Price Upside/Downside
Current Multiple 0.9 MYR0.7
0%
3-Year Average 0.9 MYR0.71
+2%
5-Year Average 1 MYR0.77
+11%
Industry Average 2.2 MYR1.76
+154%
Country Average 1.3 MYR1.05
+51%

Forward P/B
Today’s price vs future total equity

Not enough data available to calculate forward P/B

Peer Comparison

All Multiples
P/B
P/E
All Countries
Close
Market Cap P/B P/E
MY
Rhone Ma Holdings Bhd
KLSE:RHONEMA
153m MYR 0.9 10.8
US
Eli Lilly and Co
NYSE:LLY
835.2B USD 31.5 40.5
US
Johnson & Johnson
NYSE:JNJ
547.8B USD 6.7 26
CH
Roche Holding AG
SIX:ROG
248.4B CHF 7.7 20.1
UK
AstraZeneca PLC
LSE:AZN
216.4B GBP 5.9 28.2
CH
Novartis AG
SIX:NOVN
218.2B CHF 5.9 19.6
US
Merck & Co Inc
NYSE:MRK
276.9B USD 5.3 15.2
IE
Endo International PLC
LSE:0Y5F
244.4B USD -58.7 -83.6
DK
Novo Nordisk A/S
CSE:NOVO B
1.2T DKK 6 11.4
US
Pfizer Inc
NYSE:PFE
153.5B USD 1.8 19.8
US
Bristol-Myers Squibb Co
NYSE:BMY
118.2B USD 6.4 16.8
P/E Multiple
Earnings Growth PEG
MY
R
Rhone Ma Holdings Bhd
KLSE:RHONEMA
Average P/E: 20.8
10.8
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
40.5
32%
1.3
US
Johnson & Johnson
NYSE:JNJ
26
8%
3.3
CH
Roche Holding AG
SIX:ROG
20.1
14%
1.4
UK
AstraZeneca PLC
LSE:AZN
28.2
25%
1.1
CH
Novartis AG
SIX:NOVN
19.6
14%
1.4
US
Merck & Co Inc
NYSE:MRK
15.2
14%
1.1
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -83.6 N/A N/A
DK
Novo Nordisk A/S
CSE:NOVO B
11.4
0%
N/A
US
Pfizer Inc
NYSE:PFE
19.8
22%
0.9
US
Bristol-Myers Squibb Co
NYSE:BMY
16.8
16%
1

Market Distribution

In line with most companies in Malaysia
Percentile
32nd
Based on 453 companies
32nd percentile
0.9
Low
0 — 0.8
Typical Range
0.8 — 2.5
High
2.5 —
Distribution Statistics
Malaysia
Min 0
30th Percentile 0.8
Median 1.3
70th Percentile 2.5
Max 2 591.7

Rhone Ma Holdings Bhd
Glance View

Market Cap
155.9m MYR
Industry
Pharmaceuticals

Rhone Ma Holdings Bhd.is an investment company, which engages in the provision of animal health products and veterinary advisory businesses and management services. The company is headquartered in Petaling Jaya, Selangor. The company went IPO on 2016-12-19. The Company’s segments include Animal health products and equipment, which is engaged in marketing, trading, distribution and manufacturing of animal health products and equipment and undertaking research and development activities related to animal health, food safety and agriculture in animal health products; Food ingredients, which is engaged in distribution and supply of food ingredients to manufacturers within the food and beverage industry, and Others, which includes provision of diagnostic laboratory analyses and consultation services to the veterinary, agriculture and food industries, provision of tests and diagnostics services for human healthcare, conduct research and development in biotechnology and distribution of human healthcare and related products, management services and business of livestock.

RHONEMA Intrinsic Value
0.989 MYR
Undervaluation 30%
Intrinsic Value
Price MYR0.695
R
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett